Biogen, Elan report cases of brain disease

Wall Street Journal (subscription required), August 1, 2008

Two multiple-sclerosis patients treated with Biogen Idec Inc.'s drug Tysabri contracted a potentially deadly brain infection. The news casts a cloud over the revival of the medicine, which was already withdrawn once over safety concerns. Biogen said it had no plans to recall the drug again or restrict its use. The company said that the two patients who contracted the ailment, progressive multifocal leukoencephalopathy, or PML, are alive.


MOST POPULAR

SPONSORED REPORTS
SPONSORED HEADLINES

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2014 a division of BLR All rights reserved.